Read More

Earnings Outlook For Aldeyra Therapeutics

Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Aldeyra Therapeutics will report an earnings per share (EPS) of $-0.31.

ALDX

Read More

Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 TRANQUILITY‑2 Trial In Dry Eye Disease And Says Intends To Submit New Drug Application For Symptoms And Three Sign Endpoints Of Dry Eye Disease

Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints of Schirmer Test (p=0.0001) and ≥10 mm Schirmer Test Responder Proportions (p<0.0001) TRANQUILITY-2 Results May Allow for the

ALDX